Use of anti-cd1 antibodies for the modulation of immune responses

Abstract

The invention provides methods for the administration of an anti-CD1 antibody for the treatment or prevention of a variety of disorders, such as autoimmune disease, viral infection, bacterial infection, parasitic infection, infection by a eukaryotic pathogen, allergy, asthma, inflammatory condition, graft versus host disease, graft rejection, immunodeficiency disease, spontaneous abortion, pregnancy, and cancer.

1 . A method of treating a disease, disorder, or infection in a non-rodent mammal, said method comprising administering to said mammal an anti-CD1 antibody or antibody fragment thereof in an amount sufficient to treat said disease, disorder, or infection; wherein said disease, disorder, or infection is an autoimmune disease, viral infection, bacterial infection, parasitic infection, infection by a eukaryotic pathogen, allergy, asthma, inflammatory condition, graft versus host disease, graft rejection, immunodeficiency disease, spontaneous abortion, or pregnancy. 
     
     
         2 . The method of  claim 1 , wherein said anti-CD1 antibody is an anti-CD1d antibody. 
     
     
         3 . The method of  claim 1 , wherein said mammal is a human. 
     
     
         4 . The method of  claim 1 , wherein said antibody or antibody fragment administration is oral, intramuscular, intravenous, intraarticular, intralesional, subcutaneous, intraperitoneal, or intralesional. 
     
     
         5 . The method of  claim 1 , wherein said viral infection is a hepatitis, picornavirus, polio, HIV, or coxsacchie infection. 
     
     
         6 . The method of  claim 1 , wherein said autoimmune disorder is diabetes, rheumatoid arthritis, lupus, pemphigus vulgaris, multiple sclerosis, myasthenia gravis, transplant rejection, or graft-versus-host disease. 
     
     
         7 . The method of  claim 1 , wherein said antibody or antibody fragment is humanized. 
     
     
         8 . A method of treating a disease, disorder, or infection in a mammal, said method comprising administering to said mammal an anti-CD1 antibody or an antibody fragment thereof in an amount sufficient to treat said disease, disorder, or infection, wherein said administering is at a dosage level that allows retention of at least 50% of the activity of CD1-reactive T cells in said mammal relative to an untreated mammal, and wherein said disease, disorder, or infection is an autoimmune disease, viral infection, bacterial infection, parasitic infection, infection by a eukaryotic pathogen, allergy, asthma, inflammatory condition, graft versus host disease, graft rejection, immunodeficiency disease, spontaneous abortion, or pregnancy. 
     
     
         9 . The method of  claim 8 , wherein said anti-CD1 antibody is an anti-CD1d antibody. 
     
     
         10 . The method of  claim 8 , wherein said mammal is a human. 
     
     
         11 . The method of  claim 8 , wherein said antibody or antibody fragment administration is oral, intramuscular, intravenous, intraarticular, intralesional, subcutaneous, intraperitoneal, or intralesional. 
     
     
         12 . The method of  claim 8 , wherein said viral infection is a hepatitis, picornavirus, polio, HIV, or coxsacchie infection. 
     
     
         13 . The method of  claim 8 , wherein said autoimmune disorder is diabetes, rheumatoid arthritis, lupus, pemphigus vulgaris, multiple sclerosis, myasthenia gravis, transplant rejection, or graft-versus-host disease. 
     
     
         14 . The method of  claim 8 , wherein said antibody or antibody fragment is humanized. 
     
     
         15 . A method for increasing the activity or number of antigen-presenting cells (APC) in a mammal, said method comprising administering to said mammal an anti-CD1 antibody or antigen-binding fragment thereof in an amount sufficient to increase the production or secretion of a cytokine by said APC or to increase the proliferation of said APC, wherein said mammal is diagnosed with or is at increased risk for an autoimmune disease, viral infection, bacterial infection, parasitic infection, or infection by a eukaryotic pathogen. 
     
     
         16 . The method of  claim 15 , wherein the secretion of a cytokine is increased by at least 50%. 
     
     
         17 . The method of  claim 15 , wherein said cytokine is IL-2, IL-4, IL-7, IL-10, IL-12, IL-13, IL-15, IL-18, IFN-α/β, IFN-γ, or GM-CSF. 
     
     
         18 . The method of  claim 15 , wherein said anti-CD1 antibody is an anti-CD1d antibody. 
     
     
         19 . The method of  claim 15 , wherein said mammal is a human. 
     
     
         20 . The method of  claim 15 , wherein said antibody or antibody fragment administration is oral, intramuscular, intravenous, intraarticular, intralesional, subcutaneous, intraperitoneal, or intralesional. 
     
     
         21 . The method of  claim 15 , wherein said viral infection is a hepatitis, picornavirus, polio, HIV, or coxsacchie infection. 
     
     
         22 . The method of  claim 15 , wherein said antibody or antibody fragment is humanized.